SCHEMBL3561504

SCHEMBL3561504

NCCN(Cc1ccc2c(c1)OCO2)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
CYP3A4 P08684 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
HPGD P15428 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPT P10636 1/20 0.50
TAS2R14 Q9NYV8 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
MC4R P32245 1/20 0.47
MC5R P33032 1/20 0.47
MC3R P41968 1/20 0.47
GAA P10253 1/20 0.47
TRPM8 Q7Z2W7 2/20 0.46
USP2 O75604 2/20 0.46
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569305 0.81 ALDH1A1 (0.49) TSHRALDH1A1SMN1; SMN2TAAR1CYP3A4
SCHEMBL4971539 0.81 ALDH1A1 (0.54) TSHRALDH1A1SMN1; SMN2CYP3A4CYP1A2
SCHEMBL4974818 0.80 ALDH1A1 (0.53) TSHRALDH1A1SMN1; SMN2CYP3A4CYP1A2
SCHEMBL9788784 0.77 GAA (0.48) TSHRALDH1A1SMN1; SMN2TAAR1CYP3A4
SCHEMBL13037128 0.77 TAAR1 (0.58) TSHRTAAR1CYP3A4CYP1A2MAPT
SCHEMBL11390038 0.77 HPGD (0.64) TSHRALDH1A1SMN1; SMN2CYP3A4CYP1A2
SCHEMBL17072329 0.76 ALDH1A1 (0.57) TSHRALDH1A1SMN1; SMN2CYP3A4CYP1A2
SCHEMBL4969501 0.76 ALDH1A1 (0.49) TSHRALDH1A1SMN1; SMN2CYP3A4CYP1A2
SCHEMBL1023411 0.73 CARM1 (0.55) TSHRALDH1A1NPSR1MC4RMC3R
SCHEMBL9788827 0.73 TRPM8 (0.62) TSHRALDH1A1SMN1; SMN2CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 TSHR 788/4885ALDH1A1 2795/4885SMN1; SMN2 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.